Details of the Drug
General Information of Drug (ID: DMP9HBO)
Drug Name |
Sucralfate
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms | SUL; Ulcerlmin; Sucralfate, Chugai; Sucralfate, Scios Nova | |||||||||||||||||||
Indication |
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL is unavailable | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 4 |
Molecular Weight | 1577.9 | ||||||||||||||||||
Topological Polar Surface Area | Not Available | |||||||||||||||||||
Rotatable Bond Count | 37 | |||||||||||||||||||
Hydrogen Bond Donor Count | 20 | |||||||||||||||||||
Hydrogen Bond Acceptor Count | 55 | |||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Acne vulgaris | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | ED80 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Same Disease as Sucralfate
Coadministration of a Drug Treating the Disease Different from Sucralfate (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7055). | ||||
---|---|---|---|---|---|
2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
3 | ClinicalTrials.gov (NCT01284647) A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis. U.S. National Institutes of Health. | ||||
4 | FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41. | ||||
5 | Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14. | ||||
6 | Clinical pipeline report, company report or official report of Ohr Pharmaceutical. | ||||
7 | DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14. | ||||
8 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
9 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
10 | Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72. | ||||
11 | US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions. | ||||
12 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
13 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | ||||
14 | Cerner Multum, Inc. "Canadian Product Information.". | ||||
15 | Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):. | ||||
16 | Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108] | ||||
17 | Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC. | ||||
18 | D'Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17. [PMID: 2886325] | ||||
19 | Product Information. Chenodal (chenodeoxycholic acid). Manchester Pharmaceutical, Fort Collins, CO. | ||||
20 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
21 | McCarthy DM "Sucralfate." N Engl J Med 325 (1991): 1017-25. [PMID: 1886624] | ||||
22 | Carver PL, Berardi RR, Knapp MJ, Rider JM, Kauffman CA, Bradley SF, Atassi M "In vivo interaction of ketoconazole and sucralfate in healthy volunteers." Antimicrob Agents Chemother 38 (1994): 326-9. [PMID: 7910724] | ||||
23 | Hava M, Hurwitz A "The relaxing effect of aluminum and lanthanum on rat and human gastric smooth muscle in vitro." Eur J Pharmacol 156 (1973): 156-61. [PMID: 4715218] | ||||
24 | Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC. | ||||
25 | Havrankova J, Lahaie R "Levothyroxine binding by sucralfate." Ann Intern Med 117 (1992): 445-6. [PMID: 1503346] | ||||
26 | Cerner Multum, Inc. "Australian Product Information.". | ||||
27 | Product Information. Xofluza (baloxavir marboxil). Genentech, South San Francisco, CA. | ||||
28 | Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54. [PMID: 8845456] | ||||
29 | Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
30 | Pedrazzoli Junior J, Pierossi M de A, Muscara MN, Dias HF, da Silva CM, Mendes FD, de Nucci G "Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers." Br J Clin Pharmacol 43 (1997): 104-8. [PMID: 9056060] | ||||
31 | Canadian Pharmacists Association. | ||||
32 | Haagsma CJ "Clinically important drug interactions with disease-modifying antirheumatic drugs." Drugs Aging 13 (1998): 281-9. [PMID: 9805209] | ||||
33 | Product Information. Cholbam (cholic acid). Manchester Pharmaceutical, Fort Collins, CO. | ||||
34 | Product Information. NegGram (nalidixic acid). Sanofi Winthrop Pharmaceuticals, New York, NY. | ||||